Fanconi anemia: A multi-age cancer susceptibility syndrome

Pediatric Health

Volumn 2, Issue 2, 2008, Pages 175-187

  Harney, Julie A ^a   Shimamura, Akiko ^b   Howlett, Niall G ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myeloid leukemia; Bone marrow failure; Chromosome instability; DNA repair; Fanconi anemia; Head and neck squamous cell carcinoma

Indexed keywords

ANDROGEN; ATM PROTEIN; ATR PROTEIN; BLOOM SYNDROME HELICASE; BRCA2 PROTEIN; DANAZOL; DNA; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP CA PROTEIN; FANCONI ANEMIA GROUP CB PROTEIN; FANCONI ANEMIA GROUP CF PROTEIN; FANCONI ANEMIA GROUP CG PROTEIN; FANCONI ANEMIA GROUP CJ PROTEIN; FANCONI ANEMIA GROUP CL PROTEIN; FANCONI ANEMIA GROUP CM PROTEIN; FANCONI ANEMIA GROUP CN PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; GENE PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR; NIBRIN; OXANDROLONE; WART VIRUS VACCINE;

AGE DISTRIBUTION; ATAXIA TELANGIECTASIA; BLOOM SYNDROME; BONE MARROW DEPRESSION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHILDHOOD CANCER; CHROMOSOMAL INSTABILITY; CONGENITAL DISORDER; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DNA REPAIR; FANCONI ANEMIA; GENE IDENTIFICATION; GENETIC COMPLEMENTATION; HEAD AND NECK CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; MUTATIONAL ANALYSIS; NIJMEGEN BREAKAGE SYNDROME; REGULATORY MECHANISM; REVIEW; SECKEL SYNDROME; SQUAMOUS CELL CARCINOMA;

EID: 45149108233     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/17455111.2.2.175     Document Type: Review

References (118)

1. Lobitz S, Velleuer E: Guido Fanconi (1892-1979): a jack of all trades. Nat. Rev. Cancer 6, 893-898 (2006).
2. Alter BP, Greene MH, Velazquez I, Rosenberg PS: Cancer in Fanconi anemia. Blood 101, 2072 (2003).
3. Kutler DI, Singh B, Satagopan J et al.: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101, 1249-1256 (2003).
4. Rosenberg PS, Greene MH, Alter BP: Cancer incidence in persons with Fanconi anemia. Blood 101, 822-826 (2003).
5. Fanconi Anemia: In: Standards of Clinical Care. Second Edition. Owen J, Frohnmayer L, Eiler ME (Eds). Fanconi anemia Research Fund, Inc., OR, USA (2003).
6. Appelbaum FR, Rowe JM, Radich J, Dick JE: Acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 62-86 (2001).
7. Meyer S, Fergusson WD, Whetton AD et al.: Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/ BRCA2 disruption. Genes Chromosomes Cancer 46, 359-372 (2007).
8. Tonnies H, Huber S, Kuhl JS, Gerlach A, Ebell W, Neitzel H: Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients; gains of the chromosomal segment 3q26q29 as an adverse risk factor. Blood 101, 3872-3874 (2003).
9. Kutler DI, Wreesmann VB, Goberdhan A et al.: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Natl Cancer Inst. 95, 1718-1721 (2003).
10. Ragin CC, Modugno F, Gollin SM: The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J. Dent. Res. 86, 104-114 (2007).
11. van Zeeburg HJ, Snijders PJ, Joenje H, Brakenhoff RH: Re: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J. Natl Cancer Inst. 96, 968; author reply 968-969 (2004).
12. van Zeeburg HJ, Snijders PJ, Pals G et al.: Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res. 65, 1271-1276 (2005).
13. Alter BP: Inherited bone marrow failure syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood. Look AT, Nathan DG, Orkin SH, Ginsburg D (Eds). Saunders WB, PA, USA, 280-365 (2003).
14. Auerbach AD: Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp. Hematol. 21, 731-733 (1993).
15. Lo Ten Foe JR, Kwee ML, Rooimans MA et al.: Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur. J. Hum. Genet. 5, 137-148 (1997).
16. Gregory JJ Jr, Wagner JE, Verlander PC et al.: Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc. Natl Acad. Sci. USA 98, 2532-2537 (2001).
17. Joenje H, Patel KJ: The emerging genetic and molecular basis of fanconi anaemia. Nat. Rev. Genet. 2, 446-459 (2001).
18. Callen E, Casado JA, Tischowitz MD et al.: A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood. 105, 1946-1949 (2005).
19. Reid S, Schindler D, Hanenberg H et al.: Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 39, 162-164 (2007).
20. Smogorzewska A, Matsuoka S, Vinciguerra P et al.: Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129, 289-301 (2007).
21. Taniguchi T, D'Andrea AD: Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107, 4223-4233 (2006).
22. Wang W: Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet. 8, 735-748 (2007).
23. Xia B, Dorsman JC, Ameziane N et al.: Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet. 39, 159-161 (2007).
24. Berwick M, Satagopan JM, Ben-Porat L et al.: Genetic heterogeneity among Fanconi Anemia heterozygotes and risk of cancer. Cancer Res. 67, 9591-9596 (2007).
25. Rahman N, Seal S, Thompson D et al.: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165-167 (2007).
26. Seal S, Thompson D, Renwick A et al.: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38, 1239-1241 (2006).
27. Tischkowitz M, Xia B, Sabbaghian N et al.: Analysis of PALB2/ FANCN-associated breast cancer families. Proc. Natl Acad. Sci. USA 104, 6788-6793 (2007).
28. Wooster R, Bignell G, Lancaster J et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
29. Verlander PC, Lin JD, Udono MU et al.: Mutation analysis of the Fanconi anemia gene FACC. Am. J. Hum. Genet. 54, 595-601 (1994).
30. Kutler DI, Auerbach AD, Satagopan J et al.: High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head Neck Surg. 129, 106-112 (2003).
31. Hirsch B, Shimamura A, Moreau L et al.: Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 103, 2554-2559 (2004).
32. Howlett NG, Taniguchi T, Olson S et al.: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609. (2002).
33. Offit K, Levran O, Mullaney B et al.: Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J. Natl Cancer Inst. 95, 1548-1551 (2003).
34. Wagner JE, Tolar J, Levran O et al.: Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 103, 3226-3229 (2004).
35. Reid S, Renwick A, Seal S et al.: Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J. Med. Genet. 42, 147-151 (2005).
36. Fornace AJ Jr, Little JB, Weichselbaum RR: DNA repair in a Fanconi's anemia fibroblast cell strain. Biochim. Biophys. Acta 561, 99-109 (1979).
37. Fujiwara Y, Tatsumi M: Repair of mitomycin C damage to DNA in mammalian cells and its impairment in Fanconi's anemia cells. Biochem Biophys. Res. Commun. 66, 592-598 (1975).
38. Rainbow AJ, Howes M: Defective repair of ultraviolet- and γ-ray-damaged DNA in Fanconi's anaemia. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 31, 191-195 (1977).
39. Garcia-Higuera I, Taniguchi T, Ganesan S et al.: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7, 249-262 (2001).
40. Timmers C, Taniguchi T, Hejna J et al.: Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol. Cell 7, 241-248 (2001).
41. Moynahan ME, Chiu JW, Koller BH, Jasin M: Brca1 controls homology-directed DNA repair. Mol Cell 4, 511-518 (1999).
42. Moynahan ME, Pierce AJ, Jasin M: BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7, 263-272 (2001).
43. Haber JE: Partners and pathways repairing a double-strand break. Trends Genet. 16, 259-264 (2000).
44. Ciccia A, Ling C, Coulthard R et al.: Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol. Cell 25, 331-343 (2007).
45. Ling C, Ishiai M, Ali AM et a.: FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J. 26, 2104-2114 (2007).
46. Meetei AR, Sechi S, Wallisch M et al.: A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol. 23, 3417-3426 (2003).
47. Meetei AR, de Winter JP, Medhurst AL et al.: A novel ubiquitin ligase is deficient in Fanconi anemia. Nat. Genet. 35, 165-170 (2003).
48. Meetei AR, Levitus M, Xue Y et al.: X-linked. inheritance of Fanconi anemia complementation group B. Nat. Genet. 36, 1219-1224 (2004).
49. Meetei AR, Medhurst AL, Ling C et al.: A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat. Genet. 37, 958-963 (2005).
50. Grompe M, van de Vrugt H: The Fanconi family adds a fraternal twin. Dev. Cell 12, 661-662 (2007).
51. Sims AE, Spiteri E, Sims RJ 3rd et al.: FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat. Struct. Mol. Biol. 14, 564-567 (2007).
52. Howlett NG, Taniguchi T, Durkin SG, D'Andrea AD, Glover TW: The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum. Mol. Genet. 14, 693-701 (2005).
53. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD: S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100, 2414-2420 (2002).
54. Wang X, Andreassen PR, D'Andrea AD: Functional Interaction of Monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol. Cell Biol. 24, 5850-5862 (2004).
55. Andreassen PP, D'Andrea AD, Taniguchi T: ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 18, 1958-1963 (2004).
56. Taniguchi T, Garcia-Higuera I, Xu B et al.: Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459-472 (2002).
57. Nijman SM, Huang TT, Dirac AM et al.: The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331-339 (2005).
58. Cantor SB, Bell DW, Ganesan S et al.: BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105, 149-160 (2001).
59. Levitus M, Waisfisz Q, Godthelp BC et al.: The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat. Genet. 37, 934-935 (2005).
60. Levran O, Attwooll C, Henry RT et al.: The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat. Genet. 37, 931-933 (2005).
61. Litman R, Peng M, Jin Z et al.: BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8, 255-265 (2005).
62. Xia B, Sheng Q, Nakanishi K et al.: Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719-729 (2006).
63. Boulton SJ: Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans. 34, 633-645 (2006).
64. Godthelp BC, Wiegant WW, Waisfisz Q et al.: Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res. 594, 39-48 (2005).
65. Nakanishi K, Yang YG, Pierce AJ et al.: Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc. Natl Acad Sci. USA 102, 1110-1115 (2005).
66. Ohashi A, Zdzienicka MZ, Chen J, Couch FJ: Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage. J. Biol. Chem. 280, 14877-14883 (2005).
67. Lehmann AR: New functions for Y family polymerases. Mol. Cell 24, 493-495 (2006).
68. Lehmann AR, Translesion synthesis in mammalian cells. Exp. Cell Res. 312. 2673-2676 (2006).
69. Niedzwiedz W, Mosedale G, Johnson M, Ong CY; Pace P, Patel KJ: The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol. Cell 15, 607-620 (2004).
70. Nojima K, Hochegger H, Saberi A et al.: Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 65, 11704-11711 (2005).
71. Hinz JM, Nham PB, Salazar EP, Thompson LH: The Fanconi anemia pathway limits the severity of muragenesis. DNA Repair (Amst) 5, 875-884 (2006).
72. Papadopoulo D, Guillouf C, Mohrenweiser H, Moustacchi E: Hypomutability in Fanconi anemia cells is associated with increased deletion frequency at the HPRT locus. Proc. Natl. Acad. Sci. USA 87, 8383-8387 (1990).
73. Papadopoulo D, Porfirio B, Moustacchi E: Mutagenic response of Fanconi's anemia cells from a defined complementation group after treatment with photoactivated bifunctional psoralens. Cancer Res. 50, 3289-3294 (1990).
74. Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ, Buchwald M: Fanconi anemia group C protein prevents apoprosis in hematopoietic cells through redox regulation of GSTP1. Nat. Med. 7, 814-820 (2001).
75. Pang Q, Christianson TA, Keeble W et al.: The Fanconi anemia complementation group C gene product: structural evidence of multifunctionality. Blood 98, 1392-1401 (2001).
76. Pang Q, Fagerlie S, Christianson TA et al.: The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by γ interferon and hematopoietic growth factors. Mol. Cell Biol. 20, 4724-4735 (2000).
77. Pang Q, Keeble W, Christianson TA, Faulkner GR, Bagby GC: FANCC interacts with Hsp70 to protect hematopoietic cells from IFN-γ/ TNF-a-mediated cytotoxicity. EMBO J. 20, 4478-4489 (2001).
78. Joenje H, Arwert F, Eriksson AW, de Koning H, Oostra AB: Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. Nature 290, 142-143 (1981).
79. Joenje H, Oostra AB: Effect of oxygen tension on chromosomal aberrations in Fanconi anaemia. Hum. Genet. 63, 99-101 (1983).
80. Nagasawa H, Little JB: Suppression of cytotoxic effect of mitomycin-C by superoxide dismutase in Fanconi's anemia and dyskeratosis congenita fibroblasts. Carcinogenesis 4, 795-799 (1983).
81. Park SJ, Ciccone SL, Beck BD et al.: Oxidative stress/damage induces multimerization and interaction of Fanconi anemia proteins. J. Biol. Chem. 279, 30053-30059 (2004).
82. Ridpath JR, Nakamura A, Tano K et al.: Cells deficient in the FANC/BRCA pathway are hypersensitive to plasm levels of formaldehyde. Cancer Res. 67, 11117-11122 (2007).
83. Sejas DP, Rani I, Qiu Y et al.: Inflammatory reactive oxygen species mediated hemopoietic suppression in Fanco-deficient mice. J. Immunol. 178, 5277-5287 (2007).
84. Zhang X, Sejas DP, Qiu Y, Williams DA, Pang Q: Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence. J Cell Sci. 120, 1572-1583 (2007).
85. Mathew CG: Fanconi anaemia genes and susceptibility to cancer. Oncogene 25, 5875-5884 (2006).
86. Wooster R, Neuhausen SL, Mangion J et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265, 2088-2090 (1994).
87. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23, 1000-1004 (2004).
88. Narayan G, Arias-Pulido H, Nandula SV et al.: Promoter hypermerhylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res. 64, 2994-2997 (2004).
89. Taniguchi T, Tischkowitz M, Amieziane N et al.: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9, 569-574 (2003).
90. Tischkowitz M, Ameziane N, Waisfisz Q et al.: Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br. J. Haematol. 123, 469-471 (2003).
91. Xie Y, de Winter JP, Waisfisz Q et al.: Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br. J. Haematol. 111, 1057-1064 (2000).
92. Tischkowitz MD, Morgan NV, Grimwade D et al.: Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 18, 420-425 (2004).
93. Meyer S, White, DJ Will AM et al.: No evidence of significant silencing of Fanconi genes FANCF and FANCB or Nijmegen breakage syndryme gene NBS1 by DNA-hyper-methyation imporadic childhood leukaemia. Br. J. Haematol. 134, 61-63 (2006).
94. Chimomas D, Taniguchi T, de la Vega M et al.: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther. 5, 952-961 (2006).
95. Kennedy RD, Chen CC, Stuckert P et al.: Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest. 117, 1440-1449 (2007).
96. Meyer S, Barber LM, White DJ et al.: Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia. Br. J. Haematol. 133, 284-292 (2006).
97. Auerbach AD, Greenbaum J, Pujara K et al.: Spectrum ofsequence variation in the FANCG gene: an International Fanconi Anemia Registry (IFAR) study. Hum. Mutat. 21, 158-168 (2003).
98. Barber LM, McGrath HE, Meyer S et al.: Constitutional sequence variation in the Fanconi anaemia group C (FANCC) gene in childhood acute myeloid leukaemia. Br. J. Haematol. 121, 57-62 (2003).
99. Condie A, Powles RL, Hudson CD et al.: Analysis of the Fanconi anaemia complementation group A gene in acute myeloid leukaemia. Leuk. Lymphoma 43, 1849-1853 (2002).
100. Savitsky K, Bar-Shira A, Gilad S et al.: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749-1753 (1995).
101. Carney JP Maser RS, Olivares H et al.: The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93, 477-486 (1998).
102. Matsuura S, Tauchi H, Nakamura A et al.: Positional cloning of the gene for Nijmegen breakage syndrome. Nat. Genet. 19, 179-181 (1998).
103. Varon R, Vissinga C, Platzer M et al.: Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93, 467-476 (1998).
104. Nakanishi K, Taniguchi T, Ranganathan V et al.: Interaction of FANCD2 and NBS1 in the DNA damage response. Nat. Cell Biol. 4, 913-920 (2002).
105. Demuth I, Digweed M: The clinical manifestation of a defective response to DNA double-strand breaks as exemplified by Nijmegen breakage syndrome. Oncogene 26, 7792-7798 (2007).
106. Chun HH, Gatti RA: Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 3, 1187-1196 (2004).
107. Taylor AM, Metcalfe JA, Thick J, Mak YF: Leukemia and lymphoma in ataxia telangiectasia. Blood 87, 423-438 (1996).
108. Ellis NA, Groden J, Ye TZ et al.: The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83, 655-666 (1995).
109. Ellis NA, Lennon DJ, Proytcheva M, Alhadeff B, Henderson EE, German J: Somatic intragenic recombination within the mutated locus BLM can correct the high sister-chromatid exchange phenotype of Bloom syndrome cells. Am. J. Hum. Genet. 57, 1019-1027 (1995).
110. Amor-Gueret M: Bloom syndrome, genomic instability and cancer: the SOS-like hypothesis. Cancer Lett 236, 1-12 (2006).
111. O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA: An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. DNA Repair (Amst) 3, 1227-1235 (2004).
112. Goodship J, Gill H, Carter J, Jackson A, Splitt M, Wright M: Autozygosity mapping of a seckel syndrome locus to chromosome 3q22. 1-q24. Am. J. Hum. Genet. 67, 498-503 (2000).
113. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA: A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat. Genet. 33, 497-501 (2003).
114. Hayani A, Suarez CR, MoInar Z, LeBeau M, Godwin J: Acute myeloid leukaemia in a patient with Seckel syndrome. J. Med. Genet. 31, 148-149 (1994).
115. Wang P, Spielberger RT, Thangavelu M et al.: dic(S;17): a recurring abnormality in malignant myeloid disorder, associated with mutations of TP53. Genes Chromosomes Cancer 20, 282-291 (1997).
116. Shechter D, Costanzo V, Gautier J: Regulation of DNA replication by ATR: signaling in response to DNA intermediates. DNA Repair (Amst) 3, 901-908 (2004).
117. Ho GP, Margossian S, Taniguchi T, D'Andrea AD: Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol. Cell Biol. 26, 7005-7015 (2006).
118. Shimamura A, Montes, de Oca R, Svenson JL et al.: A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100, 4649-4654 (2002).